Pemigatinib – Medxy AI

Pemigatinib demonstrates high efficacy and manageable toxicity in treating MLN-FGFR1, especially in chronic-phase patients, addressing a critical unmet need in this aggressive neoplasm.

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity
Pemigatinib: A Breakthrough Targeted Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements
Promising Immunogenicity and Safety of the Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers
Optimizing Smoking Cessation in Major Depressive Disorder: Varenicline Outperforms Bupropion and Nicotine Patch with Comparable Safety
Evaluating the Role of AI Tools in Pharmacy Students’ OSCE Performance and Anxiety: Insights from a Randomized Controlled Trial

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

aging AI artificial intelligence blood pressure breast cancer cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials COVID-19 Dementia diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy longevity MASH MASLD mental health Mortality NAFLD nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial sexual health stroke sức khỏe sức khỏe tim mạch thử nghiệm lâm sàng treatment type 2 diabetes weight loss wellness women's health

Your health, we care

Scroll to Top